Tech Company Financing Transactions
NextCure Funding Round
Hillhouse Capital Group, Quan Capital and Alexandria Venture Investments joined a $93 million Series B funding round for NextCure. The round was recorded on 11/14/2018.
Transaction Overview
Company Name
Announced On
11/14/2018
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds will be primarily used to support clinical development for the company's two lead drug candidates, including NC318, preclinical development of additional novel immunomedicine drug candidates, and the Company's activities under its previously announced collaboration with Eli Lilly and Company to discover and develop novel cancer targets with the Company's proprietary FIND-IO platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9000 Virginia Manor Rd. 200
New Haven, CT 20705
USA
New Haven, CT 20705
USA
Phone
Website
Email Address
Overview
NextCure (Nasdaq: NXTC), launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/14/2018: CoverCress venture capital transaction
Next: 11/14/2018: AsclepiX Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs